Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial
So now its not just that youre eating less, you are also burning more
Monthly follow-ups (15-20 min): Titrate dose, manage side effects, provide behavioral support, track progress
As with Ozempic, any potential side effects, including hair-related concerns, should be discussed with a healthcare provider
This article examines the relationship between Wegovy, weight loss, and reproductive health, alongside essential safety considerations for those planning conception
53% achieved a weight reduction of 15%, compared with 5% in the placebo group